Population Pharmacokinetic Model of Adalimumab Based on Prior Information Using Real World Data

Adalimumab is a fully human monoclonal antibody used for the treatment of inflammatory bowel disease (IBD). Due to its considerably variable pharmacokinetics and the risk of developing antibodies against adalimumab, it is highly recommended to use a model-informed precision dosing approach. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquez-Megias, Silvia, Nalda-Molina, Ricardo, Más-Serrano, Patricio, Ramon-Lopez, Amelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604709/
https://www.ncbi.nlm.nih.gov/pubmed/37893195
http://dx.doi.org/10.3390/biomedicines11102822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604709/
https://www.ncbi.nlm.nih.gov/pubmed/37893195
http://dx.doi.org/10.3390/biomedicines11102822

Ejemplares similares